A new approval uses a blood-detected resistance mutation to guide a treatment change in a specific form of advanced breast cancer.
FDA Approves a Mutation-Guided Breast Cancer Treatment
On September 4, 2026, the U.S. Food and Drug Administration granted accelerated approval to Etcamah, the brand name for camizestrant, in combination with a CDK4/6 inhibitor for a narrowly defined group of adults with advanced breast cancer.
The approval applies to hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during treatment with an aromatase inhibitor plus a CDK4/6 inhibitor. The mutation must be identified with an FDA-authorized test. Camizestrant is used with abemaciclib, palbociclib, or ribociclib—not as a stand-alone replacement for the entire treatment plan.
This is not an approval for every person with breast cancer. It is a targeted strategy for tumors that develop a particular form of treatment resistance while a person is receiving a specific therapy combination.
What Are HR-Positive, HER2-Negative Breast Cancers?
Hormone receptor-positive breast cancer grows in response to hormones such as estrogen. HER2-negative means the cancer does not have excessive HER2 protein driving its growth. This is a common biological subtype of breast cancer, but patients within the group can have different mutations, treatment histories, and patterns of disease.
For locally advanced or metastatic disease, endocrine therapy is often combined with a CDK4/6 inhibitor. Aromatase inhibitors lower estrogen production, while CDK4/6 inhibitors slow signals that cancer cells use to divide. The combination can control disease for a meaningful period, but tumors may eventually evolve and become resistant.
Why ESR1 Mutations Matter
ESR1 is the gene that provides instructions for the estrogen receptor. Certain ESR1 mutations can allow the receptor to remain active even when estrogen levels are reduced by an aromatase inhibitor. That can make the current endocrine therapy less effective.
According to the FDA, fewer than 5% of people have an ESR1 mutation when HR-positive metastatic breast cancer is first diagnosed, but the mutation may be found in nearly 40% after progression on an aromatase inhibitor. It is therefore often an acquired resistance change rather than a feature present from the beginning.
The new approval is notable because it uses circulating tumor DNA, or ctDNA, to detect the resistance mutation in blood before routine imaging necessarily shows that the cancer has progressed.
How the Blood Test Fits Into Treatment
Tumors release small fragments of DNA into the bloodstream. A liquid biopsy can analyze that ctDNA for selected mutations. For this approval, the FDA authorized the Guardant360 CDx assay as a companion diagnostic to identify eligible ESR1 mutations.
A positive result does not determine treatment by itself. The oncology team must interpret the result alongside the exact cancer subtype, medications, response to therapy, symptoms, other health conditions, and the test’s technical limitations.
Testing also does not mean that every possible cancer change is detected. A person should not stop an aromatase inhibitor, start camizestrant, or change a CDK4/6 inhibitor without a treatment decision from the oncology team.
What Did the SERENA-6 Trial Find?
The approval was supported by SERENA-6, a randomized study that monitored patients for an emerging ESR1 mutation while they were receiving an aromatase inhibitor plus a CDK4/6 inhibitor. When the mutation appeared in blood before imaging documented progression, participants either switched the aromatase inhibitor to camizestrant while continuing a CDK4/6 inhibitor or continued the existing combination.
The FDA reported an estimated median progression-free survival of 16.0 months in the camizestrant combination group and 9.2 months in the group that continued an aromatase inhibitor plus a CDK4/6 inhibitor. Progression-free survival measures how long people lived without the cancer worsening by the study’s criteria; it is not the same as a cure or proof of longer overall survival.
The result supports the idea that changing endocrine therapy when molecular resistance appears may delay progression in this selected population.
What Accelerated Approval Means
Accelerated approval allows the FDA to approve a treatment for a serious condition based on an intermediate outcome that is considered reasonably likely to predict clinical benefit. It can provide earlier access while additional evidence is collected.
In this case, the approval rests on progression-free survival after the ESR1 mutation was detected. The FDA specifically stated that it is not yet confirmed whether switching treatment at this molecular stage, rather than waiting for confirmed disease progression, produces a clinically meaningful benefit. Confirmatory studies are required.
That distinction matters. The treatment is legally approved for the stated indication, but evidence development is not finished. Future studies must verify and describe the benefit.
Safety and Monitoring
The FDA announcement says camizestrant prescribing information includes a boxed warning about the risk of an irregular heart rhythm when it is used with certain medications. The labeling also includes warnings and precautions for an abnormally slow heart rate and potential harm to an unborn baby.
An oncology team should review a patient’s full medication and supplement list for interactions, assess reproductive considerations where relevant, and decide what heart-rate or rhythm monitoring is appropriate. Side effects, new symptoms, or questions about pregnancy prevention should be discussed promptly with the treating team.
No one should change or discontinue cancer treatment because of a news report. The balance of benefit and risk depends on the individual clinical situation.
Who Might Be Eligible?
Eligibility requires several features at the same time: adulthood; HR-positive, HER2-negative locally advanced or metastatic breast cancer; current treatment with an aromatase inhibitor and a CDK4/6 inhibitor; detection of an eligible ESR1 mutation during that therapy; and testing with an FDA-authorized companion diagnostic.
People with early-stage disease, a different breast cancer subtype, no qualifying ESR1 mutation, or a different treatment situation are not automatically candidates. Even within the approved group, the oncology team must determine whether the regimen is appropriate.
Questions Patients Can Ask Their Oncology Team
Useful questions include whether ESR1 testing is appropriate now, which test would be used, what a positive or negative result would mean, how camizestrant would fit with the current CDK4/6 inhibitor, what monitoring is needed, and what alternatives are available.
Patients can also ask how the trial outcome relates to their goals and what remains unknown about overall survival, long-term safety, and the timing of a treatment switch.
The Bottom Line
Camizestrant represents a new FDA-approved, mutation-guided option for a specific group of adults with HR-positive, HER2-negative advanced breast cancer. The strategy uses an ESR1 mutation detected in blood to guide a change in endocrine therapy before imaging necessarily shows progression.
The randomized trial showed longer progression-free survival with the camizestrant combination, but accelerated approval does not mean the treatment is a cure or that every breast cancer patient should receive it. Confirmatory evidence is still required, and all testing and treatment decisions belong in an individualized discussion with an oncology team.
This content is for educational purposes only and is not a substitute for professional medical advice.